KYNB Kyntra Bio, Inc. Common Stock

XNAS 4.39 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

KYNB $4.39 —
Key stats
$4.39
52-Week Range
$4.36 – $9.70
YTD
-53.79%
Straddle Price
$0.00
P/C Vol Ratio
0.00
Market Cap
$0.0B
Open
$4.60
Day Range
$4.36 – $4.65
Volume
30,072
Prev Close
$4.58
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.25
Cost of Equity (CAPM)11.85% (VRP-adj)
WACC11.77%
Volatility Risk Premium+520.7pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-607.7%
Book / Price-169.1%
Gross Margin (TTM)40.7%
FCF Margin (TTM)-511.7%
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$6.88 (Market Anchor value)
SMA 20 / Bollinger Mid$5.72
Bollinger Width / SMA20789.3% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
60-Day Conviction
85%
20-Day Fair Value
≈ by Nov 25, 2026
$4.58
α +1.7% rank 79%
conviction
84%
40-Day Fair Value
≈ by Dec 24, 2026
$4.64
α +3.1% rank 89%
conviction
87%
60-Day Fair Value
≈ by Jan 22, 2027
$4.65
α +3.4% rank 88%
conviction
85%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $6.88 100% stability 85% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
34
List Date
2014-11-14
CIK
0000921299
Next Earnings
2026-11-09 (After-Close)
EPS Forecast
($3.66) (3 est.)
Headquarters
San Francisco, CA
Homepage
https://www.kyntrabio.com

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'26Avg
Jan-17.05%-17.05%
Feb-15.07%-15.07%
Mar-3.83%-3.83%
Apr2.39%2.39%
May-2.68%-2.68%
Jun9.42%9.42%
Jul-11.33%-11.33%
Aug15.09%15.09%
Sep-16.35%-16.35%
Oct-30.77%*-30.77%
Nov----
Dec----
Total-56.34%-56.34%
* Only 1 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $5.72
SMA 50: $6.88
SMA 200: $7.19
Current: $4.50
EMA 12: $5.27
EMA 26: $5.88
MACD: -0.6087 | Signal: -0.0767
BEARISH
ADX (14): 55.41
STRONG TREND
+DI: 7.68
−DI: 42.18

Momentum Oscillators

RSI (14): 22.00
OVERSOLD
Stoch %K: 10.43
Stoch %D: 15.62
Williams %R: -92.96

Volume & Volatility

BB Upper: $7.01
BB Lower: $4.43
NEUTRAL
OBV: -432,130
Vol SMA 20: 25,152
Vol ROC: 27.63%
ATR: $0.38
True Range: $0.29
HV 20: 70.7%
HV 30: 61.7%
HV 60: 55.8%

Data Summary

Data Points: 201
Last Updated:
Date Range: 2026-01-08T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All KYNB news →
Earnings History
3 of 3 under expected move
Avg Expected Move
52.68%
Avg Actual Move
2.53%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-03-16 After-Close 45.71% 5.29% 0.12x Within
2026-05-11 Pre-Market 84.62% 2.16% 0.03x Within
2026-08-13 After-Close 27.70% 0.14% 0.01x Within

Earnings calendar: this week’s reports with expected vs actual moves →

KYNB Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $0.00
7-DTE Move: $0.00
Days to Exp: 81 (2027-01-15)

Options Flow

Call Volume: 27
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 3,057
Put OI: 393
P/C OI: 0.129
Total OI: 3,450

ATM Options Pricing

ATM Call: $0.00
ATM Put: $0.00
Call %: 0.0%
Put %: 0.0%

Chain Summary

Chain Volume: 27
Chain OI: 3,450
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Jan 9 · No data
30 DTE / 10d —
— pts EXTREME
as of Jan 9 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.00Oct 26
Beta Analysis

Risk Metrics

Beta: 1.1442
Alpha: -97.25%
Correlation: 0.2963
R-Squared: 8.8%
Stock Volatility: 50.4%
Market Volatility: 13.1%

Analysis Details

Benchmark: SPY
Data Points: 200
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own KYNB
1 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$204K
0.00%
#2878 of 3138-1.5%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

KYNB Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 4,044,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

31 filers1,181,143 shares$9.14M value29.21% of float
# Filer Shares Value % of Total % of Float Period
1 ARMISTICE CAPITAL, LLC 400,000 $3.02M 33.04% 9.89% 2026-06-30
2 Vanguard Group Inc Custodian 181,973 $1.60M 17.48% 4.50% 2025-12-31
3 Vanguard Capital Management LLC 159,950 $1.21M 13.21% 3.96% 2026-06-30
4 ACADIAN ASSET MANAGEMENT LLC 105,585 $795.00K 8.70% 2.61% 2026-06-30
5 BlackRock, Inc. Custodian 84,330 $636.69K 6.97% 2.09% 2026-06-30
6 Geode Capital Management, LLC Custodian 43,219 $326.38K 3.57% 1.07% 2026-06-30
7 HighTower Advisors, LLC 39,746 $300.08K 3.28% 0.98% 2026-06-30
8 Two Sigma Investments, LP Custodian 39,511 $298.31K 3.26% 0.98% 2026-06-30
9 RENAISSANCE TECHNOLOGIES LLC 27,081 $204.46K 2.24% 0.67% 2026-06-30
10 Vanguard Fiduciary Trust Co 24,105 $181.99K 1.99% 0.60% 2026-06-30
11 Birchview Capital, LP 22,566 $170.37K 1.86% 0.56% 2026-06-30
12 State Street Corp 20,284 $153.14K 1.68% 0.50% 2026-06-30
13 GSA CAPITAL PARTNERS LLP 15,697 $119.00K 1.30% 0.39% 2026-06-30
14 UBS Group AG Custodian 7,857 $59.32K 0.65% 0.19% 2026-06-30
15 GROUP ONE TRADING LLC Custodian 4,406 $33.27K 0.36% 0.11% 2026-06-30
16 Vanguard Global Advisers, LLC 1,424 $10.75K 0.12% 0.04% 2026-06-30
17 Tower Research Capital LLC (TRC) Custodian 1,113 $8.40K 0.09% 0.03% 2026-06-30
18 Axiom Investment Management LLC 704 $5.32K 0.06% 0.02% 2026-06-30
19 Morgan Stanley Custodian 487 $3.68K 0.04% 0.01% 2026-06-30
20 CIBC Private Wealth Group LLC 287 $2.52K 0.03% <0.01% 2025-12-31
21 HARBOUR INVESTMENTS, INC. 200 $1.51K 0.02% <0.01% 2026-06-30
22 National Bank of Canada Custodian 193 $1.45K 0.02% <0.01% 2026-06-30
23 OSAIC HOLDINGS, INC. Custodian 182 $1.37K 0.01% <0.01% 2026-06-30
24 Royal Bank of Canada Custodian 138 $1.00K 0.01% <0.01% 2026-06-30
25 BNP Paribas Financial Markets Custodian 46 $347 <0.01% <0.01% 2026-06-30
3 filers$872.18K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $674.97K 77.39% 2026-06-30
2 Wolverine Trading, LLC Custodian $142.85K 16.38% 2025-09-30
3 GROUP ONE TRADING LLC Custodian $54.36K 6.23% 2026-06-30
# Filer Notional Value % of Total Period

KYNB Insider Trading (Form 4)

Latest: 2026-10-06
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-06 Andrew E. Singer Director Grant (A) +14,000 opt — EDGAR
2026-09-09 David DeLucia Chief Financial Officer Tax (F) −22 $8.55 -$188 EDGAR
2026-09-09 Thane Wettig CEO Tax (F) −209 $8.55 -$1.8K EDGAR
2026-06-17 Michael Kauffman Director Grant (A) +7,000 opt — EDGAR
2026-06-17 Jeffrey L Edwards Director Grant (A) +7,000 opt — EDGAR
2026-06-17 Maykin Ho Director Grant (A) +7,000 opt — EDGAR
2026-06-17 James A Schoeneck Director Grant (A) +7,000 opt — EDGAR
2026-06-09 Thane Wettig CEO Tax (F) −198 $6.71 -$1.3K EDGAR
2026-06-09 David DeLucia Chief Financial Officer Tax (F) −52 $6.71 -$349 EDGAR
2026-05-19 Thane Wettig CEO Buy (P) +2,800 $7.09 $19.9K EDGAR
2026-05-18 Thane Wettig CEO Buy (P) −2,800 $7.09 -$19.9K EDGAR
2026-03-10 David DeLucia Chief Financial Officer Tax (F) −60 $6.84 -$410 EDGAR
2026-03-10 Thane Wettig CEO Tax (F) −277 $6.84 -$1.9K EDGAR
2026-02-05 Thane Wettig CEO Grant (A) +60,000 opt — EDGAR
2026-02-05 David DeLucia Chief Financial Officer Grant (A) +26,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

KYNB Insider Holdings

2 insiders · @ $4.50
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Thane Wettig CEO 26,836 $120.8K $0 6 2026-09-09
2 David DeLucia Chief Financial Officer 4,355 $19.6K $0 4 2026-09-09
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

KYNB Board & Officers

As of SEC filings through Oct 6, 2026

Directors 6

Officers 2

Changes in the last 10 years (36)
Oct 1, 2026Andrew E. Singer became a director
Jun 4, 2025The company announced the departure of Aoife Brennan from the board in an SEC filing
Jun 4, 2025Michael Kauffman became a director
Dec 16, 2024David DeLucia became Chief Financial Officer
Sep 12, 2024The company announced the departure of Suzanne Blaug from the board in an SEC filing
Sep 12, 2024The company announced the departure of Gerald Lema from the board in an SEC filing
Sep 12, 2024The company announced the departure of Benjamin Cravatt from the board in an SEC filing
Aug 30, 2024The company announced the departure of Juan Graham as Chief Financial Officer in an SEC filing
Aug 30, 2024The company announced the departure of Deyaa Adib as Chief Medical Officer in an SEC filing
Apr 22, 2024Deyaa Adib became Chief Medical Officer
Mar 25, 2024Thane Wettig first listed as a director in an SEC filing
Nov 3, 2023Thane Wettig listed as CEO (previously Interim CEO) in SEC filings
Sep 8, 2023Thane Wettig listed as Interim CEO (previously Chief Commercial Officer) in SEC filings
Aug 31, 2023The company announced the departure of Mark Eisner as EVP, Chief Medical Officer in an SEC filing
Jul 21, 2023The company announced the departure of Enrique A Conterno from the board in an SEC filing
Jul 21, 2023The company announced the departure of Enrique A Conterno as Chief Executive Officer in an SEC filing
Jun 5, 2023Mark Eisner listed as EVP, Chief Medical Officer (previously Chief Medical Officer) in SEC filings
Jun 5, 2022The company announced the departure of Thomas F Kearns Jr from the board in an SEC filing
Oct 6, 2021Mark Eisner listed as Chief Medical Officer (previously Incoming Chief Medical Officer) in SEC filings
Sep 9, 2021Pat Cotroneo reported in an SEC filing no longer being SVP, Finance and CFO
Not reported recently (10)
  • Christine Chung · Last reported as SVP, China Operations in an SEC filing dated Mar 7, 2025
  • Jeffrey William Henderson · Last reported as a director in an SEC filing dated Sep 6, 2023
  • Rory B Riggs · Last reported as a director in an SEC filing dated May 28, 2021
  • Kalevi Kurkijarvi · Last reported as a director in an SEC filing dated May 28, 2021
  • Elias Kouchakji · Last reported as SVP, Clinical Dev, Drug Safety in an SEC filing dated Mar 10, 2021
  • K Peony Yu · Last reported as Chief Medical Officer in an SEC filing dated Dec 17, 2020
  • Roberto Pedro Rosenkranz · Last reported as a director in an SEC filing dated Jun 11, 2020
  • Thomas B Neff · Last reported as a director in an SEC filing dated Aug 23, 2019
  • Toshinari Tamura · Last reported as a director in an SEC filing dated Jun 7, 2019
  • Jorma Routti · Last reported as a director in an SEC filing dated Mar 27, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

KYNB Proposed Insider Sales (Form 144)

Latest: 2023-09-01
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-09-01 Jeffrey Henderson Director 2,000 $2.1K 2023-09-01 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2023-08-04 Jeffrey Henderson Director 2,000 $3.8K 2023-08-04 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2023-07-11 Jeffrey Henderson Director 2,000 $5.5K 2023-07-11 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2023-06-23 Wettig Thane Officer 791 $13.1K 2023-06-23 ETRADE FINANCIALCORPORATION — EDGAR
2023-06-13 Christine Chung Officer 62,500 $1.10M 2023-06-13 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2023-06-09 AOIFE BRENNAN Director 4,733 $81.4K 2023-06-09 E*TRADE FINANCIAL CORPORATION 10b5-1 EDGAR
2023-06-09 SUZANNE BLAUG Director 8,520 $146.6K 2023-06-09 E*TRADE FINANCIAL CORPORATION 10b5-1 EDGAR
2023-06-09 JEFFREY L EDWARDS Director 7,889 $135.6K 2023-06-09 E*TRADE FINANCIAL CORPORATION 10b5-1 EDGAR
2023-06-09 BENJAMIN CRAVATT Director 3,944 $67.7K 2023-06-09 E*TRADE FINANCIAL CORPORATION 10b5-1 EDGAR
2023-06-08 Jeffrey Henderson Director 7,000 $124.5K 2023-06-08 Goldman Sachs & Co. LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
2 ETFs hold KYNB
2 shown · $1.04M total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $759,290 — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $281,062 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
0.11
TTM Diluted EPS
$40.44
TTM Revenue
$7.44M
TTM Net Income
$163.62M
TTM Op. Cash Flow
$-21.38M
Quarterly figures (1 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$3.74M$-15.20M$-3.76$-13.89M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-12
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
0.11
P/B
—
P/S
2.45
EV/EBITDA
—
EV/Sales
-2.53
ROE
—
ROA
149.2%
Div Yield
0.00%
FCF Yield
-117.49%
Debt/Equity
—
Current Ratio
—
Market Cap
$18.20M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
100.04K
SI % of Float
2.58%
Days to Cover
3.74
Short Vol Ratio
35.0%
Free Float
3.88M
Float %
95.7%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-08